法瑟姆制药 PHAT
$5.25 +$0.17 (+3.35%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $5.25 0.00%
开盘$5.26
昨收$5.08
当日区间$5.04 – $5.31
成交量1.77M
市值$426.78M
市盈率（TTM）–
股息率–
PHAT 相关新闻
匹配 Phathom Pharmaceuticals 或代码 PHAT 的头条新闻，按最新排序。
- Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10
- H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)
- H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
- Barclays Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $14 负面
- Raymond James Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $21 负面
- Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $20
- Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $22 负面
- Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $22 负面
- Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $0.00 per Share, Vs. FactSet Est of $-0.19
- Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
- Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $25
- Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating
- Barclays Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $18
- A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28
- Barclays Upgrades Phathom Pharmaceuticals(PHAT.US) to Buy Rating, Raises Target Price to $18 正面
暂无评论——快来第一个聊聊 PHAT。